Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2

Sponsor Class

NIH 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2Endocrine 1

Conditions

Breast Neoplasms 552Neoplasms 502Carcinoma, Non-Small-Cell Lung 419Prostatic Neoplasms 326Colorectal Neoplasms 310Lung Neoplasms 280Neoplasm Metastasis 233Leukemia, Myeloid, Acute 222Ovarian Neoplasms 205Pancreatic Neoplasms 195Multiple Myeloma 186Recurrence 141Squamous Cell Carcinoma of Head and Neck 140Brain Neoplasms 139Stomach Neoplasms 138Melanoma 132Carcinoma, Hepatocellular 130Endometrial Neoplasms 127Glioblastoma 124Triple Negative Breast Neoplasms 116Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Hematologic Neoplasms 102Head and Neck Neoplasms 100Urinary Bladder Neoplasms 98Carcinoma, Renal Cell 98Lymphoma 97Glioma 94Sarcoma 93Esophageal Neoplasms 90Uterine Cervical Neoplasms 88

Interventions

atezolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Erlotinib Hydrochloride 1Disulfides 1Contrast Media 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Hereditary leiomyomatosis and renal cell cancer × 90 days × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT00001238 2026-05-22

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

National Institutes of Health Clinical Center (CC)

Recruiting
5,000 enrolled
EndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, Kidney Neoplasms, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡